Apples and oranges. Re: 7.4-year update of the ongoing bicalutamide Early Prostate Cancer (EPC) trial programme.

about

Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer: part 2. Final evaluation of the Scandinavian Prostatic Cancer Group (SPCG) Study No. 5

P2860

Q28277569-3CC297DE-E540-437F-BD9A-F0197F508186

P2860

Apples and oranges. Re: 7.4-year update of the ongoing bicalutamide Early Prostate Cancer (EPC) trial programme.

Item

http://www.wikidata.org/entity/Q46936634

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年学术文章

@wuu

2006年学术文章

@zh

2006年学术文章

@zh-cn

2006年学术文章

@zh-hans

2006年学术文章

@zh-my

2006年学术文章

@zh-sg

2006年學術文章

@yue

2006年學術文章

@zh-hant

name

Apples and oranges. Re: 7.4-ye ...... Cancer (EPC) trial programme.

@en

Apples and oranges. Re: 7.4-year update of the ongoing bicalutamide Early Prostate Cancer

@nl

type

Item

label

Apples and oranges. Re: 7.4-ye ...... Cancer (EPC) trial programme.

@en

Apples and oranges. Re: 7.4-year update of the ongoing bicalutamide Early Prostate Cancer

@nl

prefLabel

Apples and oranges. Re: 7.4-ye ...... Cancer (EPC) trial programme.

@en

Apples and oranges. Re: 7.4-year update of the ongoing bicalutamide Early Prostate Cancer

@nl

P1476

Apples and oranges. Re: 7.4-ye ...... Cancer (EPC) trial programme.

@en

P2093

Cora N Sternberg

http://www.w3.org/2001/XMLSchema#string

P2860

Structural basis for antagonism and resistance of bicalutamide in prostate cancer

Molecular determinants of resistance to antiandrogen therapy

Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate.

Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program.

6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.

Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3-year median followup from the Scandinavian Prostate Cancer Group Study Number 6.

Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer.

Algorithms for prostate-specific antigen recurrence after treatment of localized prostate cancer.

Prediction of progression: nomograms of clinical utility.

Risks and benefits of hormonal manipulation as monotherapy or adjuvant treatment in localised prostate cancer.

P304

435-438

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1464-410X.2006.06088.X

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2006-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16469001

http://www.w3.org/2001/XMLSchema#string

Apples and oranges. Re: 7.4-year update of the ongoing bicalutamide Early Prostate Cancer (EPC) trial programme.

about

P2860

P2860

Apples and oranges. Re: 7.4-year update of the ongoing bicalutamide Early Prostate Cancer (EPC) trial programme.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698